Pharmaceuticals, Biotechnology and Life Sciences
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of 6,000,000 shares…
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board…
DUBLIN–(BUSINESS WIRE)–The “Global Musculoskeletal Disorders Drugs Market Report 2019″ report has been added to ResearchAndMarkets.com’s offering. Global Musculoskeletal Disorders Drugs…
BOULDER, Colo.–(BUSINESS WIRE)–OnKure, Inc., the leader in discovery and development of selective histone deacetylase inhibitors, entered into an exclusive license…
Phase 1 Data Presented Today at IAS 2019 KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United…
SEATTLE–(BUSINESS WIRE)–#AdultStemCells–According to Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,342.0 million in 2018,…
Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.
Camurus said Monday that the United States District Court for the District of Columbia granted Braeburn’s motion for summary judgement, vacating the U.S. Food and Drug Administration’s (FDA) decision to block final market approval of Brixadi Monthly.
Highlights from the review: T cell immunogens are Next Generation influenza vaccines and antigen specific rheumatoid arthritis (RA) therapy will…
LONDON–(BUSINESS WIRE)–#Healthcare–Governments across the world are taking initiatives to increase awareness and provide funding for the development of new drugs…